$5.52
0.00% today
Nasdaq, Jun 27, 01:10 pm CET
ISIN
US0162591038
Symbol
ALIM
Sector
Industry

Alimera Sciences, Inc. Share price

$5.52
+2.57 87.12% 1M
+1.71 44.88% 6M
+1.20 27.78% YTD
+2.75 99.28% 1Y
-3.78 40.65% 3Y
-8.58 60.84% 5Y
-85.83 93.96% 10Y
Nasdaq, Closing price Wed, Jun 26 2024
ISIN
US0162591038
Symbol
ALIM
Sector
Industry

Key figures

Market capitalization $289.18m
Enterprise Value $347.09m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.85
P/S ratio (TTM) P/S ratio 3.21
P/B ratio (TTM) P/B ratio 7.11
Sales growth (TTM) Sales growth 61.75%
Turnover (TTM) Turnover $90.22m
EBIT (operating result TTM) EBIT $-295.00k
Free cash flow (TTM) Free cash flow $-12.89m
Cash position $14.35m
EPS (TTM) EPS $-1.57
P/E ratio expected negative
P/S ratio expected 2.73
EV/Sales expected 3.27
Short interest 0.51%
Show more

Is Alimera Sciences, Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,947 shares worldwide.

Alimera Sciences, Inc. Share analysis

Unlock scores for free

Analyst opinions

4 Analysts have issued a Alimera Sciences, Inc. forecast:

4x Hold
100%

Analyst opinions

4 Analysts have issued a Alimera Sciences, Inc. forecast:

Hold
100%

Financial data from Alimera Sciences, Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
90 90
62% 62%
100%
- Direct costs 23 23
112% 112%
26%
67 67
50% 50%
74%
- Selling and administrative expenses 39 39
9% 9%
43%
- Research and development costs 17 17
0% 0%
19%
11 11
234% 234%
12%
- Depreciation and amortization 11 11
313% 313%
12%
EBIT (operating result) EBIT -0.30 -0.30
97% 97%
0%
Net profit -21 -21
25% 25%
-24%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Alimera Sciences, Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Alimera Sciences, Inc. Share News

Neutral
Accesswire
about 12 hours ago
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in ...
Neutral
PRNewsWire
3 days ago
MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
Positive
InvestorPlace
3 days ago
Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
More Alimera Sciences, Inc. News

Company profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Head office United States
CEO Richard Eiswirth
Employees 159
Founded 2003
Website www.alimerasciences.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now